Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Deals

LinkedCare Raises Hundreds of Millions in Series E Funding Led by State-Owned Investors

Fineline Cube Jan 8, 2025

LinkedCare, a consumer healthcare SaaS+ supply chain platform based in Shanghai, has reportedly raised “hundreds...

Company Deals

Grand Life Sciences Partners with Cali Biosciences for CPL-01 Commercialization in China

Fineline Cube Jan 8, 2025

China-based Grand Life Sciences has entered into a partnership with compatriot firm Cali Biosciences Co.,...

Company Drug

Insilico Medicine’s ISM5411 Shows Positive Results in Phase I Studies for Inflammatory Bowel Disease

Fineline Cube Jan 8, 2025

China’s generative artificial intelligence (AI)-driven biotech, Insilico Medicine, has announced positive preliminary results from two...

Company Deals

GlycoNex Licenses SPD8 Biosimilar to Undisclosed Company for Osteoporosis Treatment

Fineline Cube Jan 8, 2025

Taiwan-based GlycoNex, Inc. (TPEx: 4168) has announced a licensing agreement with an undisclosed company for...

Company Drug

Yiling Pharmaceutical Withdraws Clinical Filing for G201-Na in Assisted Reproduction

Fineline Cube Jan 8, 2025

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced the withdrawal of its clinical filing...

Company Drug

Dizal’s Sunvozertinib Receives Priority Review from FDA for EGFR Exon 20 NSCLC

Fineline Cube Jan 8, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...

Company Deals

Boehringer Ingelheim and Sutro Achieve Commercial-Scale Manufacturing of Luvelta

Fineline Cube Jan 8, 2025

Boehringer Ingelheim BioXcellence and Sutro Biopharma Inc. have announced the successful application of Sutro’s proprietary...

Company Deals

Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases

Fineline Cube Jan 8, 2025

US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE:...

Company Deals

AbbVie Exercises Option for Capsida’s Neurodegenerative Disease Program

Fineline Cube Jan 8, 2025

US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option...

Company Medical Device

Eyebright Medical’s Loong Crystal PR Receives NMPA Class III Medical Device Approval

Fineline Cube Jan 8, 2025

China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050) has announced that it has received...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approvals for ADC SYS6045 and PDE4B Inhibitor SYH2059

Fineline Cube Jan 8, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received separate clinical...

Company Drug

Kelun-Biotech’s Anti-HER2 ADC A166 Receives NMPA Review for Expanded Indication

Fineline Cube Jan 8, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that another indication approval filing for...

Company Deals

PostEra Expands Partnership with Pfizer to Launch New ADC Collaboration

Fineline Cube Jan 8, 2025

PostEra, a Boston-based biotech company powered by machine learning, has announced an expanded partnership with...

Company Deals

Merck KGaA Adopts Quris AI’s Bio-AI Platform for Drug Development Pipeline

Fineline Cube Jan 8, 2025

Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced...

Company Drug

Hansoh and GSK’s HS-20093 Receives FDA Breakthrough Therapy Designation for Osteosarcoma

Fineline Cube Jan 8, 2025

China-based Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692) and its UK partner GSK plc (LON:...

Company Deals

Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co. Launch Strategic Partnership for Linagliptin

Fineline Cube Jan 7, 2025

On January 7, Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607,...

Company Deals

Merck KGaA Completes Acquisition of HUB Organoids, Expanding Cell Culture Portfolio

Fineline Cube Jan 7, 2025

German major Merck KGaA (ETR: MRK) announced the completion of its acquisition of Holland-based HUB...

Company Drug

Amgen’s Imdylltra Gains Conditional Approval in UK for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Jan 7, 2025

US biotech company Amgen (NASDAQ: AMGN) has received conditional approval from the UK’s Medicines and...

Company Deals

Mabwell Bioscience Files for IPO on Hong Kong Stock Exchange, Expanding Biopharma Reach

Fineline Cube Jan 7, 2025

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has officially filed for an initial public offering...

Company Deals

WuXi Biologics to Sell Irish Vaccine Assets to MSD for USD 500 Million

Fineline Cube Jan 7, 2025

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) is poised to...

Posts pagination

1 … 284 285 286 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.